Buparlisib Hydrochloride - 10mM in DMSO, high purity , CAS No.1312445-63-8(DMSO)

Item Number

B655274

• Specifications & Purity: 10mM in DMSO
• Storage Temp: Desiccated,Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC 50 of 52 nM/166 nM/116 nM/262 nM for p110α / p110β / p110δ / p110γ , respectively.

In Vitro

Buparlisib (BKM120) exhibits 50-300 nM activity for class I PI3K’s, including the most common p110α mutants. Additionally, NVP-BKM120 exhibits lower potency against class III and class IV PI3K's, where 2, 5, >5, and >25 μM biochemical activity is observed for inhibition of VPS34, mTOR, DNAPK, and PI4K, respectively. Buparlisib (BKM120) induces multiple myeloma (MM) cell apoptosis in both dose- and time-dependent manners. Buparlisib (BKM120) at concentrations ≥10 μM induces significant apoptosis in all tested MM cell lines at 24 h (P<0.05, compares with control). Therefore, 10 μM Buparlisib (BKM120) and 24-h treatment are chose in in the following experiments if not stated otherwise. Buparlisib (BKM120) treatment results in a dose-dependent growth inhibition in all tested MM cell lines. Buparlisib (BKM120) IC 50 varies among tested MM cells. At 24 h treatment, IC 50 for ARP-1, ARK, and MM.1R is between 1 and 10 μM, while IC 50 for MM.1S is <1 μM, and IC 50 for U266 is between 10 and 100 μM. In summary, Buparlisib (BKM120) treatment results in MM cell growth inhibition and apoptosis in dose- and time-dependent manners. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In A2780 xenograft tumors, oral dosing of Buparlisib (BKM120) at 3, 10, 30, 60, and 100 mg/kg results in a dose dependent modulation of pAKT Ser473 . Partial inhibition of pAKT Ser473 is observed at 3 and 10 mg/kg, and near complete inhibition is observed at doses of 30, 60, or 100 mg/kg, respectively. Inhibition of pAKT (normalized to total AKT) tracked well with both plasma and tumor drug exposure . Mice receiving Buparlisib (BKM120) (5 μM per kg per day for 15 days) treatment has significantly smaller tumor burdens as compare with control mice, which are measured as tumor volume (P<0.05) and level of circulating human kappa chain (P<0.05). In addition, Buparlisib (BKM120) treatment significantly prolongs the survival of tumor-bearing mice (P<0.05). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal administration

Mice Six- to eight-week-old female severe combined immunodeficiency (SCID) mice are used. SCID mice are subcutaneously inoculated in the right flank with 1 million ARP-1 or MM.1S cells suspended in 50 μL phosphate-buffered saline (PBS). After palpable tumor developed (tumor diameter ≥5 mm), mice are treated with intraperitoneal injection of DMSO/PBS or Buparlisib (BKM120) (5 μM per kg per day) for 15 days. Tumor sizes are measured every 5 days, and blood samples are collected at the same period. Tumor burdens are evaluated by measuring tumor size and detecting circulating human kappa chain or lambda chain. aladdin has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:p110α 52 nM (IC 50 ) p110α-H1047R 58 nM (IC 50 ) p110α-E545K 99 nM (IC 50 ) p110δ 116 nM (IC 50 ) p110β 166 nM (IC 50 ) p110γ 262 nM (IC 50 ) Vps34 2.4 μM (IC 50 ) mTOR 4.6 μM (IC 50 )